Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice

Pharmacological Research

Volumn 110, Issue , 2016, Pages 181-192

  Palomo Garo, Cristina ^a,b,c   Gómez Gálvez, Yolanda ^a,b,c   García, Concepción ^a,b,c   Fernández Ruiz, Javier ^a,b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

Author keywords

Autophagy; Cannabinoids; CB2 receptors; Endocannabinoid signaling system; LRRK2 transgenic mice; Parkinson'disease

Indexed keywords

4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; LEUCINE RICH REPEAT KINASE 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; ANTIPARKINSON AGENT; CANNABINOID RECEPTOR AGONIST; CNR2 PROTEIN, MOUSE; LRRK2 PROTEIN, HUMAN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; AUTOPHAGY; BASAL GANGLION; CELL LOSS; CLINICAL FEATURE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DISEASE MODEL; DRUG TARGETING; DYSTONIA; GENE MUTATION; GLIOSIS; HYPOKINESIA; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; MUSCLE WEAKNESS; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; ROTAROD TEST; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TRANSGENIC MOUSE; TRANSNEURONAL DEGENERATION; AGE; AGONISTS; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; MALE; METABOLISM; MOTOR ACTIVITY; MUSCLE STRENGTH; MUTATION; PARKINSONISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE;

AGE FACTORS; ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; BEHAVIOR, ANIMAL; CANNABINOID RECEPTOR AGONISTS; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; GENETIC PREDISPOSITION TO DISEASE; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MALE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUSCLE STRENGTH; MUTATION; PARKINSONIAN DISORDERS; PHENOTYPE; RECEPTOR, CANNABINOID, CB2; ROTAROD PERFORMANCE TEST; SIGNAL TRANSDUCTION;

EID: 84964345977     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.04.004     Document Type: Article

References (53)

1. V. Chiurchiù, A. Leuti, and M. Maccarrone Cannabinoid signaling and neuroinflammatory diseases: a melting pot for the regulation of brain immune responses J. Neuroimmune Pharmacol. 10 2015 268 280
2. J. Fernández-Ruiz, M.A. Moro, and J. Martínez-Orgado Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications Neurotherapeutics 12 2015 793 806
3. Y.C. Chung, E. Bok, S.H. Huh, J.Y. Park, S.H. Yoon, S.R. Kim, and et al. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation J. Immunol. 187 2011 6508 6517
4. M. Fidaleo, F. Fanelli, M.P. Ceru, and S. Moreno Neuroprotective properties of peroxisome proliferator-activated receptor-α (PPARα) and its lipid ligands Curr. Med. Chem. 21 2014 2803 2821
5. J.M. Duarte, S.G. Ferreira, R.A. Carvalho, R.A. Cunha, and A. Köfalvi CB receptor activation inhibits neuronal and astrocytic intermediary metabolism in the rat hippocampus Neurochem. Int. 60 2012 1 8
6. S.R. Smith, C. Terminelli, and G. Denhardt Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice J. Pharmacol. Exp. Ther. 293 2000 136 150
7. F. Molina-Holgado, E. Pinteaux, J.D. Moore, E. Molina-Holgado, C. Guaza, R.M. Gibson, and et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia J. Neurosci. 23 2003 6470 6474
8. W.S. Sheng, S. Hu, H.T. Ni, R.B. Rock, and P.K. Peterson WIN55,212-2 inhibits production of CX3CL1 by human astrocytes: involvement of p38 MAP kinase J. Neuroimmune Pharmacol. 4 2009 244 248
9. E.J. Carrier, C.S. Kearn, A.J. Barkmeier, N.M. Breese, W. Yang, K. Nithipatikom, and et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism Mol. Pharmacol. 65 2004 999 1007
10. D.A. Price, A.A. Martinez, A. Seillier, W. Koek, Y. Acosta, E. Fernández, and et al. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease Eur. J. Neurosci. 29 2009 2177 2186
11. Y. Gómez-Gálvez, C. Palomo-Garo, J. Fernández-Ruiz, and C. García Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease Prog. Neuropsychopharmacol. Biol. Psychiatry 64 2016 200 208
12. 9-THCV in animal models of Parkinson's disease Br. J. Pharmacol. 163 2011 1495 1506
13. R.M. Concannon, B.N. Okine, D.P. Finn, and E. Dowd Differential upregulation of the cannabinoid CB receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease Exp. Neurol. 269 2015 133 141
14. 2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine Neurobiol. Aging 33 421 2012 e1 e16
15. R. Kumaran, and M.R. Cookson Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease Hum. Mol. Genet. 24 2015 R32 R44
16. A. Zimprich, S. Biskup, P. Leitner, P. Lichtner, M. Farrer, S. Lincoln, and et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology Neuron 44 2004 601 607
17. C. Paisán-Ruíz, S. Jain, E.W. Evans, W.P. Gilks, J. Simón, M. van der Brug, and et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease Neuron 44 2004 595 600
18. E. Meylan, and J. Tschopp The RIP kinases: crucial integrators of cellular stress Trends Biochem. Sci. 30 2005 151 159
19. F. Gillardon, R. Schmid, and H. Draheim Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity Neuroscience 208 2012 41 48
20. M.S. Moehle, P.J. Webber, T. Tse, N. Sukar, D.G. Standaert, T.M. DeSilva, and et al. LRRK2 inhibition attenuates microglial inflammatory responses J. Neurosci. 32 2012 1602 1611
21. R. López de Maturana, J.C. Aguila, A. Sousa, N. Vázquez, P. Del Rio, A. Aiastui, and et al. Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the inflammatory response in idiopathic and genetic Parkinson's disease Neurobiol. Aging 35 2014 1116 1124
22. B. Kim, M.S. Yang, D. Choi, J.H. Kim, H.S. Kim, W. Seol, and et al. Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia PLoS One 7 2012 e34693
23. F. Gillardon Leucine-rich repeat kinase 2 phosphorylates brain tubulin-β isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration? J. Neurochem. 110 2009 1514 1522
24. E. Ohta, F. Kawakami, M. Kubo, and F. Obata LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations FEBS Lett. 585 2011 2165 2170
25. C.J. Gloeckner, A. Schumacher, K. Boldt, and M. Ueffing The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro J. Neurochem. 109 2009 959 968
26. S. Kamikawaji, G. Ito, and T. Iwatsubo Identification of the autophosphorylation sites of LRRK2 Biochemistry 48 2009 10963 10975
27. D. Ramonet, J.P. Daher, B.M. Lin, K. Stafa, J. Kim, R. Banerjee, and et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2 PLoS One 6 2011 e18568
28. C.Y. Chen, Y.H. Weng, K.Y. Chien, K.J. Lin, T.H. Yeh, Y.P. Cheng, and et al. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD Cell Death Differ. 19 2012 1623 1633
29. J.S. Chou, C.Y. Chen, Y.L. Chen, Y.H. Weng, T.H. Yeh, C.S. Lu, and et al. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse Neurobiol. Dis. 68 2014 190 199
30. M. Garcia-Miralles, J. Coomaraswamy, K. Häbig, M.C. Herzig, N. Funk, F. Gillardon, and et al. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019 mutant LRRK2 and in human fibroblasts PLoS One 10 2015 e0118947
31. M. Yue, K.M. Hinkle, P. Davies, E. Trushina, F.C. Fiesel, T.A. Christenson, and et al. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice Neurobiol. Dis. 78 2015 172 195
32. G. Liu, C. Sgobio, X. Gu, L. Sun, X. Lin, J. Yu, and et al. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression Hum. Mol. Genet. 24 2015 5299 52312
33. E. Grünblatt, S. Zehetmayer, C.P. Jacob, T. Müller, W.H. Jost, and P. Riederer Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease J. Neural. Transm. 117 2010 1387 1393
34. P. Teismann, K. Tieu, D.K. Choi, D.C. Wu, A. Naini, S. Hunot, and et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration Proc. Natl. Acad. Sci. U. S. A. 100 2003 5473 5478
35. A.L. De Lella Ezcurra, M. Chertoff, C. Ferrari, M. Graciarena, and F. Pitossi Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation Neurobiol. Dis. 37 2010 630 640
36. E.D. Plowey, and C.T. Chu Synaptic dysfunction in genetic models of Parkinson's isease: a role for autophagy? Neurobiol. Dis. 43 2011 60 67
37. L.N. Hockey, B.S. Kilpatrick, E.R. Eden, Y. Lin-Moshier, G.C. Brailoiu, E. Brailoiu, and et al. Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition J. Cell Sci. 128 2015 232 238
38. A. Silva-Fernandes, S. Duarte-Silva, A. Neves-Carvalho, M. Amorim, C. Soares-Cunha, P. Oliveira, and et al. Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-joseph disease Neurotherapeutics 11 2014 433 449
39. S. Yang, C. Xia, S. Li, L. Du, L. Zhang, and Y. Hu Mitochondrial dysfunction driven by the LRRK2-mediated pathway is associated with loss of Purkinje cells and motor coordination deficits in diabetic rat model Cell Death Dis. 5 2014 e1217
40. H. Chen, E. Jacobs, M.A. Schwarzschild, M.L. McCullough, E.E. Calle, M.J. Thun, and et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease Ann. Neurol. 58 2005 963 967
41. Y. Ouchi, E. Yoshikawa, Y. Sekine, M. Futatsubashi, T. Kanno, T. Ogusu, and et al. Microglial activation and dopamine terminal loss in early Parkinson's disease Ann. Neurol. 57 2005 168 175
42. D.Y. Choi, M. Liu, R.L. Hunter, W.A. Cass, J.D. Pandya, P.G. Sullivan, and et al. Striatal neuroinflammation promotes Parkinsonism in rats PLoS One 4 2009 e5482
43. R.L. Hunter, B. Cheng, D.Y. Choi, M. Liu, S. Liu, W.A. Cass, and et al. Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice J. Neurosci. Res. 87 2009 1913 1921
44. E. Greggio, L. Civiero, M. Bisaglia, and L. Bubacco Parkinson's disease and immune system: is the culprit LRRKing in the periphery? J. Neuroinflammation 9 94 2012
45. S. Oliván, A.C. Calvo, S. Gasco, M.J. Muñoz, P. Zaragoza, and R. Osta Time-point dependent activation of autophagy and the UPS in SOD1G93A mice skeletal muscle PLoS One 10 2015 e0134830
46. C. Hiebel, and C. Behl The complex modulation of lysosomal degradation pathways by cannabinoid receptors 1 and 2 Life Sci. 138 2015 3 7
47. C. Rodríguez-Cueto, C. Benito, J. Fernández-Ruiz, J. Romero, M.L. Hernández-Gálvez, and M. Gómez-Ruiz Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias Br. J. Pharmacol. 171 2014 1472 1489
48. A. Ferry, P. Joanne, W. Hadj-Said, A. Vignaud, A. Lilienbaum, C. Hourdé, and et al. Advances in the understanding of skeletal muscle weakness in murine models of diseases affecting nerve-evoked muscle activity, motor neurons, synapses and myofibers Neuromuscul. Disord. 24 2014 960 972
49. L. Hanus, A. Breuer, S. Tchilibon, S. Shiloah, D. Goldenberg, M. Horowitz, and et al. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor Proc. Natl. Acad. Sci. U. S. A. 96 1999 14228 14233
50. M. Rinaldi-Carmona, F. Barth, J. Millan, J.M. Derocq, P. Casellas, C. Congy, and et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor J. Pharmacol. Exp. Ther. 284 1998 644 650
51. C. Monville, E.M. Torres, and S.B. Dunnett Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model J. Neurosci. Methods 158 2006 219 223
52. E.A. Del Bel, A.S. Souza, F.S. Guimarães, C.A. da-Silva, and L.P. Nucci-da-Silva Motor effects of acute and chronic inhibition of nitric oxide synthesis in mice Psychopharmacology (Berl.) 161 2002 32 37
53. K. Matsuura, H. Kabuto, H. Makino, and N. Ogawa Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion J. Neurosci. Methods 73 1997 45 48